Literature DB >> 28945827

HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma.

A S Koksal1, B Toka1, A T Eminler1, I Hacibekiroglu2, M I Uslan1, E Parlak1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28945827     DOI： 10.1093/annonc/mdx502

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  17 in total

Review 1.  HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications.

Authors:  Carolina Boni; Valeria Barili; Greta Acerbi; Marzia Rossi; Andrea Vecchi; Diletta Laccabue; Amalia Penna; Gabriele Missale; Carlo Ferrari; Paola Fisicaro
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

Review 2.  Reactivation of hepatitis B virus infection in patients with hematologic disorders.

Authors:  Bo Wang; Ghulam Mufti; Kosh Agarwal
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

3.  Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.

Authors:  Dan Pu; Liyuan Yin; Yuwen Zhou; Wen Li; Lin Huang; Liang Cai; Qinghua Zhou
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

4.  Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.

Authors:  Neil J Shah; Ghassan Al-Shbool; Matthew Blackburn; Michael Cook; Anas Belouali; Stephen V Liu; Subha Madhavan; Aiwu Ruth He; Michael B Atkins; Geoffrey T Gibney; Chul Kim
Journal:  J Immunother Cancer       Date:  2019-12-17       Impact factor: 13.751

Review 5.  Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy.

Authors:  Dimitrios C Ziogas; Frosso Kostantinou; Evangelos Cholongitas; Amalia Anastasopoulou; Panagiotis Diamantopoulos; John Haanen; Helen Gogas
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

6.  Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Ethan A Burns; Ibrahim N Muhsen; Kartik Anand; Jiaqiong Xu; Godsfavour Umoru; Abeer N Arain; Maen Abdelrahim
Journal:  J Immunother       Date:  2021-04-01       Impact factor: 4.912

Review 7.  HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies.

Authors:  Xing Cao; Yafei Wang; Panyun Li; Wei Huang; Xiaojuan Lu; Hongda Lu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

8.  Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.

Authors:  Xuanye Zhang; Yixin Zhou; Chen Chen; Wenfeng Fang; Xiuyu Cai; Xiaoshi Zhang; Ming Zhao; Bei Zhang; Wenqi Jiang; Zuan Lin; Yuxiang Ma; Yunpeng Yang; Yan Huang; Hongyun Zhao; Ruihua Xu; Shaodong Hong; Li Zhang
Journal:  J Immunother Cancer       Date:  2019-11-21       Impact factor: 13.751

Review 9.  Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.

Authors:  Juwhan Choi; Sung Yong Lee
Journal:  Immune Netw       Date:  2020-02-17       Impact factor: 6.303

10.  Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.

Authors:  Pei-Chang Lee; Yee Chao; Ming-Huang Chen; Keng-Hsin Lan; I-Cheng Lee; Ming-Chih Hou; Yi-Hsiang Huang
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.